%0 Journal Article
%T CEA TCB: A novel head-to-tail 2:1 T cell bispecific antibody for treatment of CEA-positive solid tumors
%A Christian Klein
%A Marina Bacac
%A Pablo Umana
%J Archive of "Oncoimmunology".
%D 2016
%R 10.1080/2162402X.2016.1203498
%X Carcinoembryonic antigen T cell bispecific antibody (CEA TCB) is a bispecific antibody used to recognize CEA and CD3e via a novel molecular format (2:1) that induces T cell-mediated killing of CEA over-expressing tumors while sparing primary cells with low CEA expression. CEA TCB treatment inhibits tumor growth and generates a highly inflamed tumor microenvironment
%K Bispecific
%K T cell
%U https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5007959/